What Happened?
Lexington, MA-based NightstaRx Resigned Matthew During as Co-Founder
About the Company
Nightstar is a private biopharmaceutical company focused on the development of therapies for retinal dystrophies. The Company’s lead programme is a retinal gene therapy for choroideremia, a rare inherited cause of blindness that affects around 1 in 50,000 people. Gene therapy has the potential to be an effective treatment for choroideremia and a range of other retinal dystrophies. The Company’s lead investors are Syncona LLP and NEA Inc. Syncona is an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to impact significantly the healthcare market of the future. NEA is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies.
About the Person
Matthew During, M.D., D.Sc., is our founder and was appointed as our chief scientific officer in March 2015 and has served as our president and a member of our board of directors since April 2014. From April 2014 to March 2015, he served as our chief executive officer. Prior to founding our company, Dr. During founded NightstaRx Limited, a pharmaceutical company, in October 2013 and served as a consultant until November 2015. From February 2014 to December 2014, Dr. During served as a senior manager at Bridgewater Associates. Prior to that, he founded Neurologix, Inc., a pharmaceutical company, in October 1999 and served as a member of its scientific advisory board until March 2012. Dr. During also co-founded Merlin Pharmaceuticals (P) Limited, a pharmaceutical company, in February 1993 and served a member of its scientific advisory board until December 1994. Dr. During previously served on the faculty of Yale University as Professor of Neurosurgery from 1989 to 2000, as a Professor at Cornell University until 2006 and Ohio State University from 2006 to December 2014, where he currently serves as an adjunct professor. Since 2011, he has also served as a visiting professor of translational neuroscience at the University of Oxford. Dr. During earned his B.S., M.D. and D.Sc. from the University of Auckland. He also completed fellowships at Massachusetts Institute of Technology and Harvard Medical School
Info Source
News
Short Profile